EP3601266
Setnar indólín-afleiður sem hindrar fyrir eftirmyndun beinbrunasóttarveiru
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
29.3.2018EP published:
28.4.2021EP application number:
18715612.0
EP translation filed:
9.6.2021Grant published:
15.7.2021EPO information:
European Patent Register
Max expiry date:
28.3.2038Expiry date:
28.3.2024Next due date:
31.3.2024
Title:
SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS
Timeline
Today
29.3.2018EP application
28.4.2021EP Publication
9.6.2021Translation submitted
15.7.2021Registration published
28.3.2024Expires
Owner
Name:
Janssen Pharmaceuticals, Inc.Address:
1125 Trenton-Harbourton Road, Titusville, NJ 08560, US
Name:
Katholieke Universiteit LeuvenAddress:
Waaistraat 6, bus 5105, 3000 Leuven, BE
Inventor
Name:
KESTELEYN, Bart Rudolf RomanieAddress:
2340 Beerse, BE
Name:
BONFANTI, Jean-FrançoisAddress:
92787 Issy-les-Moulineaux Cedex 9, FR
Name:
COESEMANS, ErwinAddress:
2340 Beerse, BE
Name:
RABOISSON, Pierre Jean-Marie BernardAddress:
2340 Beerse, BE
Name:
MARCHAND, Arnaud Didier MAddress:
3001 Leuven (Heverlee), BE
Name:
BARDIOT, Dorothée Alice Marie-EveAddress:
3001 Leuven (Heverlee), BE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
17164048Date:
31.3.2017Country:
EP
Classification
Categories:
C07D 403/12, A61P 31/14, A61P 31/12, A61K 31/4196, A61K 45/06
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 8.2.2022
Expires: 28.3.2023
Payer: Árnason Faktor ehf.
Number: 6
Paid: 8.2.2023
Expires: 28.3.2024
Payer: Árnason Faktor ehf.